Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
WALTHAM, Mass. - Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company with impressive gross profit margins of 93.63% and a strong balance sheet showing more cash than debt, announced today the initiation of a discovery program to develop a monoclonal antibody (mAb) for the treatment of measles, responding to inquiries from healthcare providers (HCPs) for an effective medicine against active measles infection and for post-exposure prophylaxis. According to InvestingPro data, the company is currently trading near its Fair Value, with analysts expecting sales growth in the current year. The biopharmaceutical company’s efforts come as a response to the lack of approved therapies for measles and the decline in vaccination rates in the U.S., which puts the country at risk of losing its measles elimination status.
The discovery program aims to address the limitations of current treatment options for measles, which include high-dose Vitamin A and immune globulin (IG) treatments that are not approved, well-characterized clinical tools. Invivyd’s goal is to identify a preclinical measles mAb candidate within 2025, with a progress update anticipated by the end of the year. With the company’s next earnings report due on May 15, 2025, investors following this development can access comprehensive analysis and 13 additional ProTips through InvestingPro’s detailed research reports.
Measles outbreaks are on the rise globally, and over 20 million unvaccinated Americans are at risk. The virus can lead to severe health consequences, including pneumonia, encephalitis, and a fatal deterioration of brain tissue known as subacute sclerosing panencephalitis. The potential health effects of declining vaccine uptake have been highlighted in recent research published in the Journal of the American Medical Association (JAMA).
Dr. Michael Mina, an infectious disease and vaccination expert, emphasized the need for effective treatments and the benefits of a monoclonal antibody approach, which can rapidly stop infection, avoid toxicities, and serve as critical prophylaxis for at-risk populations.
Marc Elia, Chairman of the Invivyd Board of Directors, stated that measles is an important potential therapeutic target and fits well with the company’s integrated capabilities in antibody discovery, development, and commercialization. Invivyd’s strategy focuses on using best-in-class pharmaceutical monoclonal antibodies to lower the burden of viral infectious diseases.
This announcement is based on a press release statement and contains forward-looking statements regarding the company’s discovery programs and the potential benefits of a measles monoclonal antibody. While analysts project the company will turn profitable this year, with an EPS forecast of $0.16 for FY2025, Invivyd’s actual results may differ materially from these statements due to various risks and uncertainties. The company’s future reports will be filed with the SEC and available at www.sec.gov. For deeper insights into Invivyd’s financial health and growth prospects, investors can access the complete Pro Research Report, available exclusively on InvestingPro, which provides comprehensive analysis of this and 1,400+ other US stocks.
In other recent news, Invivyd, Inc. announced a $30 million loan agreement with Silicon Valley Bank to support the development of its COVID-19 antibody candidate, VYD2311. This financial move aims to bolster Invivyd’s efforts in advancing its monoclonal antibody pipeline, particularly focusing on VYD2311, which is designed for intramuscular administration. The company also highlighted that its existing monoclonal antibody, PEMGARDA™, continues to show efficacy against prevalent SARS-CoV-2 variants. However, Invivyd faced a setback as the FDA declined to expand the Emergency Use Authorization for PEMGARDA to include treatment for certain immunocompromised patients with mild-to-moderate COVID-19. Despite this, the EUA for pre-exposure prophylaxis remains unaffected. Additionally, Invivyd announced Ajay Royan’s appointment to its Board of Directors, bringing expertise from his venture capital background. The company remains committed to addressing unmet medical needs in viral infectious diseases. These developments reflect Invivyd’s strategic direction and ongoing regulatory interactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.